Efficacy and safety of dihydroartemisinin-piperaquine

被引：80

作者：

Myint, H. Y.

Ashley, E. A.

Day, N. P. J.

Nosten, F.

White, N. J.

机构：

[1] Mahidol Univ, Fac Trop Med, Bangkok 10400, Thailand

[2] Epictr, Paris, France

[3] Churchill Hosp, Ctr Vaccinol & Trop Med, Oxford OX3 7LJ, England

[4] Shoklo Malaria Res Unit, Mae Sot, Thailand

来源：

TRANSACTIONS OF THE ROYAL SOCIETY OF TROPICAL MEDICINE AND HYGIENE | 2007年 / 101卷 / 09期

基金：

英国惠康基金;

关键词：

falciparum malaria; multidrug resistance; dihydroartemisinin-piperaquine; Antimalarials; efficacy; southeast Asia;

D O I：

10.1016/j.trstmh.2007.05.018

中图分类号：

R1 [预防医学、卫生学];

学科分类号：

1004 ; 120402 ;

摘要：

Dihydroartemisinin-piperaquine, a fixed-dose combination antimalarial, is an inexpensive, safe and highly effective treatment for uncomplicated falciparum or vivax malaria. Efficacy assessed over 28-63 days has consistently exceeded 95% in the treatment of multidrug-resistant falciparum malaria. More than 2600 patients have been treated with this combination in prospective studies, mainly in Southeast Asia. Toterabitity was uniformly good, and no serious adverse effects have been identified. The dosing regimen has been simplified from four doses to once daily over 3 days. More information on efficacy in Africa, and more pharmacokinetic and efficacy data in children are needed. (c) 2007 Royal. Society of Tropical Medicine and Hygiene. Published by Etsevier Ltd. All rights reserved.

引用

页码：858 / 866

页数：9

共 38 条

[31] BISQUINOLINES .1. N,N-BIS(7-CHLOROQUINOLIN-4-YL)ALKANEDIAMINES WITH POTENTIAL AGAINST CHLOROQUINE-RESISTANT MALARIA [J].